Recommendations of the Panel on Cost-effectiveness in Health and Medicine - PubMed (original) (raw)
Review
. 1996 Oct 16;276(15):1253-8.
Affiliations
- PMID: 8849754
Review
Recommendations of the Panel on Cost-effectiveness in Health and Medicine
M C Weinstein et al. JAMA. 1996.
Abstract
Objective: To develop consensus-based recommendations for the conduct of cost-effectiveness analysis (CEA). This article, the second in a 3-part series, describes the basis for recommendations constituting the reference case analysis, the set of practices developed to guide CEAs that inform societal resource allocation decisions, and the content of these recommendations.
Participants: The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, was convened by the US Public Health Service (PHS).
Evidence: The panel reviewed the theoretical foundations of CEA, current practices, and alternative methods used in analyses. Recommendations were developed on the basis of theory where possible, but tempered by ethical and pragmatic considerations, as well as the needs of users.
Consensus process: The panel developed recommendations through 2 1/2 years of discussions. Comments on preliminary drafts prepared by panel working groups were solicited from federal government methodologists, health agency officials, and academic methodologists.
Conclusions: The panel's methodological recommendations address (1) components belonging in the numerator and denominator of a cost-effectiveness (C/E) ratio; (2) measuring resource use in the numerator of a C/E ratio; (3) valuing health consequences in the denominator of a C/E ratio; (4) estimating effectiveness of interventions; (5) incorporating time preference and discounting; and (6) handling uncertainty. Recommendations are subject to the ¿rule of reason,¿ balancing the burden engendered by a practice with its importance to a study. If researchers follow a standard set of methods in CEA, the quality and comparability of studies, and their ultimate utility, can be much improved.
Comment in
- Cost-effectiveness analyses of statistically ineffective treatments.
Trippoli S, Messori A. Trippoli S, et al. JAMA. 1998 Dec 16;280(23):1992-3. doi: 10.1001/jama.280.23.1992-a. JAMA. 1998. PMID: 9863846 No abstract available.
Similar articles
- The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. Russell LB, et al. JAMA. 1996 Oct 9;276(14):1172-7. JAMA. 1996. PMID: 8827972 Review. - Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.
Siegel JE, Weinstein MC, Russell LB, Gold MR. Siegel JE, et al. JAMA. 1996 Oct 23-30;276(16):1339-41. doi: 10.1001/jama.276.16.1339. JAMA. 1996. PMID: 8861994 Review. - Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.
Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Siegel JE, et al. Pharmacoeconomics. 1997 Feb;11(2):159-68. doi: 10.2165/00019053-199711020-00005. Pharmacoeconomics. 1997. PMID: 10172935 Review. - Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I, Coast J, Brown J. Griebsch I, et al. Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127. Pediatrics. 2005. PMID: 15867026 Review. - Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Sanders GD, et al. JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195. JAMA. 2016. PMID: 27623463
Cited by
- What is needed to eliminate new pediatric HIV infections: the contribution of model-based analyses.
Doherty K, Ciaranello A. Doherty K, et al. Curr Opin HIV AIDS. 2013 Sep;8(5):457-66. doi: 10.1097/COH.0b013e328362db0d. Curr Opin HIV AIDS. 2013. PMID: 23743788 Free PMC article. Review. - Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.
Saret CJ, Winn AN, Shah G, Parsons SK, Lin PJ, Cohen JT, Neumann PJ. Saret CJ, et al. Blood. 2015 Mar 19;125(12):1866-9. doi: 10.1182/blood-2014-07-592832. Epub 2015 Feb 5. Blood. 2015. PMID: 25655601 Free PMC article. Review. - The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007).
Wong WB, Ramsey SD, Barlow WE, Garrison LP Jr, Veenstra DL. Wong WB, et al. Contemp Clin Trials. 2012 Nov;33(6):1117-23. doi: 10.1016/j.cct.2012.08.006. Epub 2012 Aug 18. Contemp Clin Trials. 2012. PMID: 22981891 Free PMC article. Clinical Trial. - Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis.
Andrews JR, Lawn SD, Dowdy DW, Walensky RP. Andrews JR, et al. Clin Infect Dis. 2013 Oct;57(7):1021-6. doi: 10.1093/cid/cit412. Epub 2013 Jun 20. Clin Infect Dis. 2013. PMID: 23788239 Free PMC article. - Modeling Healthcare Costs Attributable to Secondhand Smoke Exposure at Home among South Korean Children.
Park J, Bae S. Park J, et al. Int J Environ Res Public Health. 2020 Jun 23;17(12):4496. doi: 10.3390/ijerph17124496. Int J Environ Res Public Health. 2020. PMID: 32585811 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources